Inicio/Acciones/PMVP

PMVP

USD

PMV Pharmaceuticals Inc. Common Stock

$1.340-0.040 (-2.899%)

Precio en Tiempo Real

Healthcare

Biotecnología

Estados Unidos

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado

Fundamentos de la Empresa

Estadísticas de Negociación

Métricas de Mercado

Apertura

$1.380

Máximo

$1.430

Mínimo

$1.320

Volumen

0.37M

Fundamentos de la Empresa

Capitalización de Mercado

71.0M

Industria

Biotecnología

País

United States

Estadísticas de Negociación

Volumen Promedio

1.26M

Bolsa

NMS

Moneda

USD

Rango de 52 Semanas

Mínimo $0.81Actual $1.340Máximo $1.84

Noticias Relacionadas

24 oct 2025 · 15:39

GlobeNewswire

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

Data presented today as an oral presentation at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Confirmed responses observed in eight tumor types spanning ovarian, lung, breast,

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

13 oct 2025 · 20:01

GlobeNewswire

PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oral presentation to highlight initial data from ongoing pivotal Phase 2 study of rezatapopt, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors harboring a TP53 Y220C